Agoracom Blog Home

Archive for the ‘Lexaria Corp.’ Category

Enertopia Makes Steady Progress as Industry Heats Up

Posted by AGORACOM-JC at 10:33 AM on Monday, August 25th, 2014

WHITEFISH, MT / August 25, 2014 / Canada’s Marihuana for Medical Purposes Regulations (“MMPR”) program has been mired in controversy since the beginning. After switching from the Medical Marihuana Access Regulations (“MMAR”) to the MMPR program in October 1, 2013, Personal Use Production Licenses (“PUPL”) and Designated Person Production Licenses (“DPPL”) were phased out on March 31, 2014.

The transition from the MMAR to the MMPR program was designed to move marijuana production out of homes and into tightly regulated corporations. Unfortunately, these dynamics translated to an immediate increase in costs for many medical marijuana patients, which led to lawsuits against Health Canada to permit home growing until a better plan was established.

In the meantime, Health Canada has approved 13 licensed producers under the MMPR program that have already begun selling product. These sales are likely to accelerate as the new MMPR program picks up steam, with the government projecting about $1.3 billion per year in revenue by 2024, while home growing operations are likely to end in the near-term following the court resolutions.

Industry Heating Up

The large potential market for licensed producers under the MMPR program has led to tremendous investor interest in the space. With four licensed producers undergoing transactions to become publicly traded, including OrganiGram Inc. (TSX-V: OGI), Mettrum Ltd., Bedrocan Canada Inc., and PharmaCan Capital, investors will have the ability to invest directly or indirectly in seven of the 13 licensed producers.

Tweed Marijuana Inc. (TSX-V: TWD) (OTC: TWJMF) was the first publicly traded licensed producer and has already achieved a market capitalization of over $100 million, as of August 2014. Many private licensed producers have also reported rising demand from fund managers and venture capital firms looking for a piece of the action, signaling investor confidence in the MMPR’s ultimate success.

With many of these publicly traded companies already reaching $50 to $100 million valuations, investors may want to take a look at promising aspiring licensed producers that may be trading at a discount. Diversification across several companies that are approved and/or seeking approval may be the best way to reduce risk in a sector that is characterized by its high volatility.

Making Steady Progress

Enertopia Corp. (OTC: ENRT), with a market cap of only $10.6 million, is an aspiring licensed producer under Canada’s MMPR program that sets itself apart from the competition. With extensive experience under the prior MMAR program, the company has experience growing and handling medical marijuana, unlike many other newer applicants, and regulators know they can trust the firm to deliver on its promises.

CannabisFN Executive Interview | Enertopia Corp. (OTCQB: ENRT) from TDM Financial on Vimeo.

The company’s three major projects are all making steady progress. Security upgrades are being installed at the Green Canvas project in Saskatchewan; design upgrades are in the works at the GTA project in Ontario in partnership with Lexaria Corp. (OTC: LXRP); and, the World of Marijuana project is awaiting its Health Canada site visit as the government continues to work through its backlog.

The company is also actively pursuing opportunities to diversify into related areas like oils, edibles, and industrial hemp markets across North America. Management hopes that these efforts to establish multiple revenue streams will reduce risk for investors and ultimately help internally finance its growth. These efforts also set the company apart from many other pure-plays in the space.

Looking Ahead

Canada’s medical marijuana space may have had a rough start, but the MMPR program appears to be picking up steam. As Health Canada’s site visits take place, many companies are also becoming acquisition targets, as evidenced by Tweed’s acquisition of Park Lane Farms following its approval earlier this month. These dynamics could justify even higher valuations for smaller firms in the space.

Enertopia has a key advantage with its MMAR operating history and experienced management team. As it continues to progress towards licensure, investors in the marijuana space may want to take a second look, including those involved with U.S.-based companies like Medical Marijuana Inc. (OTC: MJNA) or Hemp Inc. (OTC: HEMP), given Canada’s more established federal-level programs.

For more information, see the following resources:

– Company Website – http://www.enertopia.com/

– CannabisFN Profile – http://www.cannabisfn.com/mdc/enertopia-corp/

Sign Up For Future Email Updates On Enertopia Corp.

http://www.tdmfinancial.com/emailassets/enrt/enrt_landing.php

Disclaimer: Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/

SOURCE: Emerging Growth LLC

Start your small cap medical marijuana research in the AGORACOM Small Cap 
Medical Marijuana Stocks Gateway: 
http://agoracom.com/portal/Small%20Cap%20Medical%20Marijuana%20Stocks

Medical pot cookie prohibition ruled unconstitutional

Posted by AGORACOM-JC at 10:31 AM on Friday, August 15th, 2014

Court challenge stems from B.C. case of Owen Smith, who was charged with trafficking for baking pot cookies

CBC News Posted: Aug 14, 2014 10:42 AM PT Last Updated: Aug 15, 2014 6:35 AM PT

Ban on medical marijuana cookies ruled unconstitutional 1:57

It’s unconstitutional to forbid licensed medical marijuana users from possessing pot-laced products, such as cookies or body creams, a B.C. Court of Appeal judge has ruled.

Parliament has been given one year to recraft regulations to allow medicinal marijuana users to use products made from cannabis extract. They can include creams, salves, oils, brownies, cakes, cookies and chocolate bars.

Health Canada currently allows people suffering from debilitating illnesses access to medicinal marijuana, but only in the form of dried marijuana.

In her written reasons, Justice Risa Levine said this specification “is arbitrary and cannot be justified in a free and democratic society.”

Levine went on to state that when patients choose to use edible forms of marijuana, it “was a matter of necessity, or put another way, the restriction to dried marijuana interfered with their physical or psychological integrity.”

Pot activists react to ruling RAW2:25

Case of the pot cookie baker

The court challenge stems from the case of Owen Smith, who was charged with trafficking for baking pot cookies and producing topical cannabis creams for a medical marijuana club in Victoria in 2009.

Smith was caught baking more than 200 pot cookies for the Victoria Cannabis Buyers Club, and had a supply of cannabis-infused cooking oils and some dried dope in his apartment when he was arrested.

Marijuana ruling - Owen Smith pot cookie bakerOwen Smith was caught baking more than 200 pot cookies for the Victoria Cannabis Buyers Club in 2009. (CHEK)

He was acquitted in April 2012 after the B.C. Supreme Court ruled the medical marijuana regulations were unconstitutional, because patients were denied access to edible pot products and derivatives.

Justice Robert Johnston concluded that permitting dried cannabis alone was arbitrary and did little to further a legitimate state interest.

Thursday’s ruling means Smith acquittal stands and he will not be retried.

Health Minister Rona Ambrose’s office said in a statement released Thursday that it is “reviewing the decision in detail and considering our options.”

Marijuana laws under the microscope

Canada currently prohibits the possession and trafficking of all marijuana products under subsection 4(1) and Schedule II of the Controlled Drugs and Substances Act. However, subsection 55(1) of this act allows for exemptions to be made.

As such, an annex to that act, the Marihuana for Medical Purposes Regulations, allow people with medical need and authorization access to medicinal marijuana.

Under these regulations, many people suffering from debilitating illnesses get marijuana through Health Canada approved companies or get permission to grow it themselves.

However, the MMPR and its predecessor, the MMAR program, limit this access to dried marijuana and do not make any other exceptions to the list of banned substances detailed in Schedule II of the Controlled Drugs and Substances Act.

These banned substances, aside from the exempted dried marijuana, include cannabis resin and various extracts and derivatives of the cannabis plant.

Ottawa had hoped the B.C. Court of Appeal would strike down the B.C. Supreme Court decision.

But under Thursday’s ruling, government has been asked to review these rules, which could mean medical marijuana users would be supplied with resin or extract or be permitted to make themselves products such as pot cookies using marijuana extracts.

RULING | Full B.C. Court of Appeal ruling on medical marijuana extract case

Source: http://www.cbc.ca/news/canada/british-columbia/medical-pot-cookie-prohibition-ruled-unconstitutional-1.2736526

Start your small cap medical marijuana research in the AGORACOM Small Cap 
Medical Marijuana Stocks Gateway: 
http://agoracom.com/portal/Small%20Cap%20Medical%20Marijuana%20Stocks

Lexaria Closes First Tranche of Financing

Posted by AGORACOM-JC at 4:20 PM on Tuesday, August 12th, 2014

Kelowna, British Columbia–(August 12, 2014) – Lexaria Corp. (OTCQB: LXRP) (CSE: LXX) (the “Company” or “Lexaria”) announces it has closed the first tranche of its Private Placement financing announced on August 9 for gross proceeds of $187,700.

Lexaria will issue 1,251,333 common shares at US$0.15 and 1,251,333 full warrants that expire on February 12, 2016 with an exercise price of US$0.25. The Company may accelerate the expiry date of the warrants if the stock price trades above CAD$0.60 cents for 20 consecutive days at any time after 6 months and one day has elapsed.

Finders’ fees of 51,000 broker’s warrants of the Company were issued, and cash finders’ fees of $7,650 were paid to various brokers.

Further announcements regarding a subsequent tranche closing, and of developments in the medical marijuana sector, will be made as information becomes available.

All issued shares will be subject to a hold period, for any resale into the USA under Rule 144, of six months and one day. Proceeds of the Private Placement will be used for general working capital, for general and administrative needs, and for corporate opportunities in the medical marijuana sector. The Private Placement is subject to normal regulatory approvals.

The securities referred to herein will not be or have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

About Lexaria

Lexaria’s shares are quoted in the USA with symbol LXRP and in Canada with symbol LXX. The company searches for projects that could provide potential above-market returns.

To learn more about Lexaria Corp. visit www.lexariaenergy.com.

FOR FURTHER INFORMATION PLEASE CONTACT:

Lexaria Corp.
Chris Bunka
Chairman & CEO
(250) 765-6424

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Access to capital, or lack thereof, is a major risk and there is no assurance that the Company will be able to raise required working capital. Current oil and gas production rates may not be sustainable and targeted production rates may not occur. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that the medical marijuana business will provide any benefit to Lexaria and no assurance that the closed financing will deliver any net benefit to the Company, nor that additional financings will be successful.

The CNSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Start your small cap medical marijuana research in the AGORACOM Small Cap 
Medical Marijuana Stocks Gateway: 
http://agoracom.com/portal/Small%20Cap%20Medical%20Marijuana%20Stocks

Lexaria Intends to Complete a $900,000 Financing

Posted by AGORACOM-JC at 9:12 AM on Friday, August 8th, 2014

Kelowna, British Columbia–(August 8, 2014) – Lexaria Corp. (OTCQB: LXRP) (CSE: LXX) (the “Company” or “Lexaria”) reports its intention to complete a non-brokered private placement financing, consisting of 6,000,000 Equity Units at US $0.15 per unit, to raise gross proceeds of up to US $900,000 (the “Private Placement”).

Each equity unit will consist of one common share of the Company and one non-transferable share purchase warrant, each warrant entitling the holder to purchase one additional common share of the Company for a period of eighteen months from the date of issuance, at a purchase price of US$0.25. The Company may accelerate the expiry date of the warrants if the stock price trades above CAD$0.60 for 20 consecutive days at any time after 6 months and one day has elapsed.

Lexaria may pay broker commissions of up to 6.0% in cash and 6% in broker warrants in connection with the Private Placement. Each broker’s warrant will be exercisable into one single common share (a “Warrant Share”) at a price of US$0.25 per Warrant Share for a period of eighteen (18) months following closing of the Offering. Certain directors, officers and insiders of the Company may participate in the Private Placement.

The Company is canceling its earlier announced intention to complete a non-brokered private placement financing, consisting of 17,000,000 Equity Units at US $0.20 per unit, to raise gross proceeds of up to US $3,400,000 (the “Private Placement”) due to market conditions and the increased dilution the larger proposed financing would have caused.

The securities issued will be subject to a hold period in Canada of four months and one day, or for any resales possible into the USA under Rule 144, six months and one day. Proceeds from the equity units will be used for corporate development in the Medical Marijuana business, G&A and general working capital. The Private Placement will be subject to normal regulatory approvals.

The securities referred to herein will not be or have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

About Lexaria

Lexaria’s shares are quoted in the USA with symbol LXRP and in Canada with symbol LXX. The company searches for projects that could provide potential above-market returns. To learn more about Lexaria Corp. visit www.lexariaenergy.com.

FOR FURTHER INFORMATION PLEASE CONTACT:

Lexaria Corp.
Chris Bunka, CEO: (250) 765-6424
Clark Kent, Media Manager: (647) 519-2646

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. It is impossible to identify all such factors but they include and are not limited to the existence of underground deposits of commercial quantities of oil and gas; cessation or delays in exploration because of mechanical, weather, operating, financial or other problems; capital expenditures that are higher than anticipated; or exploration opportunities being fewer than currently anticipated. There can be no assurance that road or site conditions will be favorable for field work; no assurance that well treatments or workovers will have any effect on oil or gas production; no assurance that oil field interconnections will have any measurable impact on oil or gas production or on field operations, and no assurance that any expected new well(s) will be drilled or have any impact on the Company. There can be no assurance that expected oil and gas production will actually materialize; and thus no assurance that expected revenue will actually occur. There is no assurance the Company will have sufficient funds to drill additional wells, or to complete acquisitions or other business transactions. Such forward looking statements also include estimated cash flows, revenue and current and/or future rates of production of oil and natural gas, which can and will fluctuate for a variety of reasons; oil and gas reserve quantities produced by third parties; and intentions to participate in future exploration drilling. Adverse weather conditions including but not limited to surface flooding can delay operations, impact production, and cause reductions in revenue. The Company may not have sufficient expertise to thoroughly exploit its oil and gas properties. The Company may not have sufficient funding to thoroughly explore, drill or develop its properties. Access to capital, or lack thereof, is a major risk and there is no assurance that the Company will be able to raise required working capital. Current oil and gas production rates may not be sustainable and targeted production rates may not occur. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that the medical marijuana business will provide any benefit to Lexaria and no assurance that the proposed financing of up to $900,000 will be successful.

The CNSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Start your small cap medical marijuana research in the AGORACOM Small Cap 
Medical Marijuana Stocks Gateway: 
http://agoracom.com/portal/Small%20Cap%20Medical%20Marijuana%20Stocks

Lexaria Announces Corporate Update

Posted by AGORACOM-JC at 8:31 AM on Tuesday, August 5th, 2014

Kelowna, British Columbia–(August 5, 2014) – Lexaria Corp. (OTCQB: LXRP) (CSE: LXX) (the “Company” or “Lexaria”) is announces that it is in the process of making all the cash and stock payments required to secure its lease of the Burlington marijuana production facility to Dec 9, 2014. This includes the issuance of 91,662 restricted common shares to the building owner as Lexaria’s portion of the lease costs.

As earlier announced, the Burlington joint venture with Enertopia Corp has received municipal approval. The Lexaria/Enertopia joint venture is for a building of approx 75,000 sq ft in total potential space available. Additional lease payments will be required after Dec 9, 2014. Progress on the joint venture continues to be made and Lexaria will report new developments soon, as they are finalized.

Separately, the Company has issued 82,031 restricted common shares to Agora Internet Relations Corp, for a quarterly payment as per an agreement originally announced in March, 2014.

Although the share issuances disclosed herein are not large, Lexaria has a policy of informing investors on every occasion when shares are issued, as changes to the Company’s capital structure are material events. It is important that shareholders have the most current information possible, and this is part of Lexaria’s continuous efforts at full transparency. After these shares are issued, Lexaria will have 32,998,357 shares issued and outstanding.

The securities referred to herein will not be or have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

About Lexaria

Lexaria’s shares are quoted in the USA with symbol LXRP and in Canada with symbol LXX. The company searches for projects that could provide potential above-market returns.

To learn more about Lexaria Corp. visit www.lexariaenergy.com.

FOR FURTHER INFORMATION PLEASE CONTACT:

Lexaria Corp. Chris Bunka, CEO: (250) 765-6424
Clark Kent, Media Inquiries: (647) 519-2646

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. It is impossible to identify all such factors but they include and are not limited to the existence of underground deposits of commercial quantities of oil and gas; cessation or delays in exploration because of mechanical, weather, operating, financial or other problems; capital expenditures that are higher than anticipated; or exploration opportunities being fewer than currently anticipated. There can be no assurance that road or site conditions will be favorable for field work; no assurance that well treatments or workovers will have any effect on oil or gas production; no assurance that oil field interconnections will have any measurable impact on oil or gas production or on field operations, and no assurance that any expected new well(s) will be drilled or have any impact on the Company. There can be no assurance that expected oil and gas production will actually materialize; and thus no assurance that expected revenue will actually occur. There is no assurance the Company will have sufficient funds to drill additional wells, or to complete acquisitions or other business transactions. Such forward looking statements also include estimated cash flows, revenue and current and/or future rates of production of oil and natural gas, which can and will fluctuate for a variety of reasons; oil and gas reserve quantities produced by third parties; and intentions to participate in future exploration drilling. Adverse weather conditions including but not limited to surface flooding can delay operations, impact production, and cause reductions in revenue. The Company may not have sufficient expertise to thoroughly exploit its oil and gas properties. The Company may not have sufficient funding to thoroughly explore, drill or develop its properties. Access to capital, or lack thereof, is a major risk and there is no assurance that the Company will be able to raise required working capital. Current oil and gas production rates may not be sustainable and targeted production rates may not occur. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that the medical marijuana business will provide any benefit to Lexaria, and no assurance that any proposed new facility will be built or proceed, nor that municipal or Health Canada regulatory approvals will be obtained. There is no assurance that any municipality where proposed facilities are located will retain its approval for a medical marijuana production facility. The Company is not currently growing or selling medical marijuana.

The CNSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Start your small cap medical marijuana research in the AGORACOM Small Cap 
Medical Marijuana Stocks Gateway: 
http://agoracom.com/portal/Small%20Cap%20Medical%20Marijuana%20Stocks

Parents of six-year-old medical marijuana user calling for legal access to marijuana oil

Posted by AGORACOM-JC at 10:11 AM on Tuesday, July 29th, 2014

CTV Ottawa

The parents of six-year-old Ottawa Constance Bay boy who suffers from a rare form of epilepsy are desperately calling for changes to Canada’s medicinal marijuana laws.

Liam McKnight’s parents are breaking the rule by giving him marijuana oil to help treat his severe seizures.

Liam has Dravet Syndrome, a rare form of epilepsy that causes him to suffer violent seizures, sometimes dozens a day.

But under Heath Canada rules, licensed producers can only produce and distribute dried marijuana.

Liam’s mother Mandy McKnight says her son is technically only allowed to smoke it or vaporize it.

But she doesn’t want Liam smoking marijuana, and she says he wouldn’t be able to anyway.

Liam is developmentally delayed, and his mother says he would not understand how to inhale it.

McKnight says the best way for Liam to receive the medical benifits of the drug is to ingest it as an oil, not to smoke it.

The strain of marijuana Liam is taking is higher in CBD, the compound that helps him, and very low in THC, the compound that produces the drug’s “high” effects.

Liam’s mom says they have tried several different medications to treat Liam’s seizures, and so far marijuana oil has been their best defence against them.

Liam’s parents are calling on the federal government to make medicinal marijuana oil legal.

Right now, they must go through the costly and lengthy process of buying the dried marijuana, having it converted into oil, then tested to check its properties so they can determine the proper dosage to give Liam.

They say they don’t know how long they can sustain that.

According to Health Canada, “current regulations for clinical trials would allow a sponsor to propose a clinical trial for extracts of cannabis. A manufacturer or another sponsor (e.g., a physician or treatment centre) can submit a clinical trial application to Health Canada at any time.”

But the McNights say they don’t have time to wait for a clinical trial.

They say last year, 14 children in their Dravet Syndrome support group passed away.

They want Liam to have easier access to the oil so his quality of life can be improved.
“I don’t understand why Health Canada is preventing him from accessing a medication that could potentially save his life, or extend it for a very long period of time,” Mandy McKnight said.

“We’re trying to do everything we can to just give him a break, and give him a chance to just be a kid,” she said. “I think it’s a viable treatment option, and he deserves a chance to try it.”

Start your small cap medical marijuana research in the AGORACOM Small Cap 
Medical Marijuana Stocks Gateway: 
http://agoracom.com/portal/Small%20Cap%20Medical%20Marijuana%20Stocks

Toronto opens first referral-only medical marijuana clinic

Posted by AGORACOM-JC at 11:26 AM on Monday, July 21st, 2014

BLAKE WOLFE | QMI AGENCY

TORONTO – Inside a brand-new medical clinic near the intersection of Yonge St. and Eglinton Ave., a patient walks up to the counter following his appointment.

An employee stands with him, offering advice on the man’s new medication.

“Be sure to grind it well before putting consuming it,” the staffer says. “You want it fluffy like dryer lint. Fluffy is your friend when it comes to vaporizers.”

The patient thanks him for the advice and heads out the door.

It’s a normal exchange at the Cannabinoid Medical Clinic — CMClinic for short — Toronto’s first referral-only medical marijuana clinic.

It was a busy first week for executive director Dr. Danial Schecter and his staff after officially opening the clinic’s doors on July 14 and seeing dozens of the approximately 700 patients on the wait list. Talk of additional clinics in Canada is already taking place, Schecter says.

The clinic opened in the wake of new federal regulations regarding medical marijuana use. The rules, which came into effect on April 1, require that patients procure their stash from an approved supplier with a doctor’s prescription.

Schecter, who learned of marijuana’s medical effects while studying at the University of Montreal, set up the Toronto clinic after successfully using the plant to treat several patients at his former practice near Georgian Bay.

“I had a patient who suffered from anxiety so badly that he literally flapped when he walked into my office,” recalled Schecter, adding that the man self-medicated with alcohol and was afraid to consume marijuana for fear of returning to prison. “I saw his treatment as a success, and when the new regulations were announced, it was an opportunity to help many more people.”

Despite criticism from some doctors and health organizations about the lack of evidence for marijuana’s medical benefits, Schecter said he hopes to change that perception by contributing to the emerging field through his work at the clinic. He explained that in his experience, family doctors fall into three categories:

The 10% who are firmly opposed to the medical use of weed, another 10% who are open to the concept but cautious, and the 80% who are willing to prescribe it as a last resort for patients who have tried everything else.

“This is something that’s talked about for maybe five or 10 minutes in medical school,” Schecter mused. “The research done here will allow us to make a solid contribution to a novel field of medicine. I’m trying to educate the skeptical physicians and help that 80% (willing to prescribe marijuana).”

While other marijuana clinics have recently sprung up in Toronto, Schecter is quick to point out that CMClinic is referral-only and is covered through OHIP, similar to other medical specialists that a patient may be referred to by their family doctor.

Clinic spokesman Bridget Best said the facility operates more as a referral and educational centre for doctors and patients who may need assistance in learning about the various forms that cannabis can take as well as the myriad consumption methods.

Schecter said that as opposed to the typical recreational user who may consume mass quantities of weed due to tolerance of the drug, his patients often manage their pain by using less than a gram per day.

While patients are free to consume marijuana in whichever way they choose, the clinic sells vaporizers (which create marijuana vapour instead of smoke) as opposed to typical head shop fare like glass pipes and bongs.

No marijuana is stored on site, Best said.

Pursuing a medication more often associated with recreational and illicit consumption is often a last resort for most of the clinic’s patients — many of whom hail from various points across the GTA and southern Ontario, while others still have inquired from as far away as Germany and Panama.

Schecter, who said that he tries to avoid prescribing pot to anyone under 25 due to the inconclusive effects of the drug on the growing brain, deals predominantly with patients in “chronic pain,” ranging from those suffering with the lingering effects of accidents and chemotherapy to those requiring palliative care.

Travelling to the clinic from Bowmanville, patient Bob Landry recalled the 2011 traffic accident that left him with lingering pain and headaches. While Landry said that he has successfully used marijuana to treat his condition after traditional prescription drugs proved either ineffective or unthinkable, he sought out the clinic to help with proper dosages.

“I tried normal painkillers first, then my doctor offered me Oxycontin — I refused,” Landry said, explaining that his cousin had died from the controversial drug. “I believe this is the solution. I prefer to acquire it legally and, this way, I know what I’m getting.

“I hope to one day return to my normal activities.”

Source: http://www.sunnewsnetwork.ca/sunnews/canada/archives/2014/07/20140720-162102.html

Medical Marijuana on BTV Headlining Abattis, Lexaria, Endexx, & Affinor Growers

Posted by AGORACOM-JC at 2:20 PM on Thursday, July 17th, 2014

Vancouver, British Columbia–(July 17, 2014) – BTV-Business Television goes on location to bring investors expert analyst commentary and stories on emerging companies for their portfolio.

Watch our investment show on TV and online to gain market insight: Full Episode

Please visit:
http://www.b-tv.com/the-btv-show/episodes.html?id=230

On BNN and FOX Business News Network on Sun July 20, 2014 – on National TV, BTV-Business Television showcases the following companies:

Abattis Bioceuticals Corp. (OTCQX: ATTBF) (CSE: ATT) – capitalizing on the growing trend toward marijuana legalization in the US and Canada by supplying and partnering with companies to employ its mass cultivation systems, extraction equipment/technology, and marketing support to licensed growers. Video(http://www.b-tv.com/features/watch-now.html?id=602)

Lexaria Corp. (OTCQB: LXRP) (CSE: LXX) – BTV visits this early adapter that’s already received municipal approval in Ontario for their first medical marijuana production facility. Video (http://www.b-tv.com/features/watch-now.html?id=603)

Endexx Corp. (OTCPINK: EDXC) – supporting the cannabis industry through technology services and compliancy platforms. Video (http://www.b-tv.com/features/watch-now.html?id=604)

Affinor Growers (CSE: AFI) – automating the food production systems in Canada and the US and endeavoring to get into the medical marijuana market. Video (http://www.b-tv.com/features/watch-now.html?id=605)

And commentary from:

Alan BrochsteinAnalyst, 420Investor on what to check in cannabis companies: video (http://www.b-tv.com/i/videos/AlanBrochsteinEp297_1.wmv). Cannabis trends: video (http://www.b-tv.com/i/videos/AlanBrochsteinEp297_2.wmv). Technology in marijuana space: video (http://www.b-tv.com/i/videos/AlanBrochsteinEp297_3.wmv). Marijuana stocks: video (http://www.b-tv.com/i/videos/AlanBrochsteinEp297_4.wmv).

Horst Hueniken – President, Dundee Agricultural Corp. on medical marijuana sector: video (http://www.b-tv.com/i/videos/HorstHuenikenEp297_1.wmv). Technology in cannabis space: video (http://www.b-tv.com/i/videos/HorstHuenikenEp297_2.wmv).

BTV, a half-hour weekly business news program, profiles emerging companies across Canada and the USA to bring investors information for their portfolio. With Host Taylor Thoen, BTV features companies at their location, interviews the company’s key executives and features their business.

BTV BROADCAST TIMES:
CANADA: BNN – Sunday, July 20 @ 9:30am & 8:00pm EST
Bell Express Vu – Sunday, Jun 20 @ 9:30am & 8:00pm EST

U.S. National: Fox Business News – Sunday, July 20 @ 5:00pm EST
America One – Saturday, July 19 @ 10am EST
Biz Television Network – Thurs. Jul 24 @ 10:00pm & 1:00am EST and Sun Jul 27 @ 12:30pm, 9:00pm & 12:00am EST

Start your small cap medical marijuana research in the AGORACOM Small Cap 
Medical Marijuana Stocks Gateway: 
http://agoracom.com/portal/Small%20Cap%20Medical%20Marijuana%20Stocks

Lexaria Intends to Complete a $5,100,000 Financing

Posted by AGORACOM-JC at 8:35 AM on Thursday, July 17th, 2014

Kelowna, British Columbia–(July 17, 2014) – Lexaria Corp. (OTCQB: LXRP) (CSE: LXX) (the “Company” or “Lexaria”) reports its intention to complete a non-brokered convertible debenture financing, to raise gross proceeds of up to US $5,100,000. The debenture will have a term with a maturity date that is one year from the offering close.

The convertible debenture will pay 2.5% per annum simple interest, quarterly in arrears. Under certain conditions, the debenture is either refundable or, at the investor’s option may be converted into either a five-year note bearing 11% per annum simple interest or into equity of the Company at the price of US$0.30.

In connection with the convertible debenture, the Company may pay broker commissions of up to 2% cash and 8% in broker warrants exercisable at US$0.50 for a period of 12 months following closing of the Offering. Certain directors, officers and insiders of the Company may participate in the Private Placement.

Any securities issued will be subject to a hold period in Canada of four months and one day, or for any resales possible into the USA under Rule 144, six months and one day. Proceeds from the convertible debenture, under certain conditions, are to be used for corporate development in the Medical Marijuana business and G&A. The convertible debenture is subject to normal regulatory approvals.

The securities referred to herein will not be or have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

About Lexaria

Lexaria’s shares are quoted in the USA with symbol LXRP and in Canada with symbol LXX. The company searches for projects that could provide potential above-market returns.

To learn more about Lexaria Corp. visit www.lexariaenergy.com.

FOR FURTHER INFORMATION PLEASE CONTACT:

Lexaria Corp.
Chris Bunka, CEO: (250) 765-6424
Clark Kent, Media Manager: (647) 519-2646

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. It is impossible to identify all such factors but they include and are not limited to the existence of underground deposits of commercial quantities of oil and gas; cessation or delays in exploration because of mechanical, weather, operating, financial or other problems; capital expenditures that are higher than anticipated; or exploration opportunities being fewer than currently anticipated. There can be no assurance that road or site conditions will be favorable for field work; no assurance that well treatments or workovers will have any effect on oil or gas production; no assurance that oil field interconnections will have any measurable impact on oil or gas production or on field operations, and no assurance that any expected new well(s) will be drilled or have any impact on the Company. There can be no assurance that expected oil and gas production will actually materialize; and thus no assurance that expected revenue will actually occur. There is no assurance the Company will have sufficient funds to drill additional wells, or to complete acquisitions or other business transactions. Such forward looking statements also include estimated cash flows, revenue and current and/or future rates of production of oil and natural gas, which can and will fluctuate for a variety of reasons; oil and gas reserve quantities produced by third parties; and intentions to participate in future exploration drilling. Adverse weather conditions including but not limited to surface flooding can delay operations, impact production, and cause reductions in revenue. The Company may not have sufficient expertise to thoroughly exploit its oil and gas properties. The Company may not have sufficient funding to thoroughly explore, drill or develop its properties. Access to capital, or lack thereof, is a major risk and there is no assurance that the Company will be able to raise required working capital. Current oil and gas production rates may not be sustainable and targeted production rates may not occur. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that the medical marijuana business will provide any benefit to Lexaria and no assurance that the proposed financing of up to $5,100,000 will be successful.

The CNSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

NOT FOR DISTRIBUTION TO US WIRE SERVICES. FOR CANADIAN DISTRIBUTION ONLY.

Start your small cap medical marijuana research in the AGORACOM Small Cap 
Medical Marijuana Stocks Gateway: 
http://agoracom.com/portal/Small%20Cap%20Medical%20Marijuana%20Stocks

Municipal Approval for Lexaria-Enertopia Joint Venture in Burlington, Ontario

Posted by AGORACOM-JC at 7:34 AM on Monday, July 14th, 2014

Kelowna, British Columbia–(Newsfile Corp. – July 14, 2014) – Lexaria Corp. (OTCQB: LXRP) (CSE: LXX) (the “Company” or “Lexaria“) is pleased to announce that the production of Medical Marihuana in compliance with Health Canada MMPR regulations has received final Municipal zoning approval for the Lexaria/Enertopia joint venture. Previously announced only as being located in the Greater Toronto Area, now that Municipal approval has been obtained Lexaria is happy to announce the facility location as Burlington, Ontario.

The evaluation procedures of the City of Burlington were followed, including presentations made to city officials and opportunities for public feedback and input. Lexaria is pleased that the City of Burlington showed community leadership and vision in implementing a thoughtful series of rules for the cultivation of medical marijuana in accordance with Federal Health Canada regulations.

“Approval by the City of Burlington for a medical marijuana production facility is an important step in the journey towards our goal of obtaining a license under Health Canada’s MMPR program and becoming a leader in the industry,” said Chris Bunka, CEO of Lexaria Corp.

Now that the City of Burlington has passed a bylaw permitting medical marijuana production facilities, Lexaria expects that the joint venture license application to Health Canada will be submitted soon.

The bylaw approving the medical marijuana facility zoning was passed by Burlington officials on June 9th, and the period of time when appeals were allowed to be heard expired on July 9, 2014. Notice of passing of the Bylaw was provided on July 10, and at this time the bylaw is in existence.

The Lexaria/Enertopia joint venture, as previously reported, is for a building of approx 30,000 sq ft for first phase design, with a right of first refusal obtained for approx another 45,000 sq ft. Since the original announcement of this facility on April 10, 2014, a great deal of progress has been made regarding the state of the art design concepts expected to be implemented.

The joint venture has engaged David Hyde & Associates for security design and implementation. David Hyde & Associates is a full service security management and business risk consulting and training practice that offers independent, high quality advisory services underpinned by real-world security and risk management experience. David Hyde & Associates, widely acknowledged as one of Canada’s leading security experts, has previously been a security consultant to another existing company that has already received their license under the MMPR program.

The joint venture has also engaged KNY Architects Inc, a design and planning firm headquartered in Burlington that has been in business for over 55 years. They have completed hundreds of projects across Canada, USA, and the Ukraine.

A total of 880,000 restricted common shares will be issued to a number of persons in accordance with previously entered agreements, upon reaching the municipal approval milestone. The securities issued will be subject to a hold period in Canada of four months and one day, or for any resales possible into the USA under Rule 144, six months and one day.

The securities referred to herein will not be or have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Separately, Lexaria has accepted the resignation of Chris Hornung as Assistant Operations Manager.

About Lexaria

Lexaria’s shares are quoted in the USA with symbol LXRP and in Canada with symbol LXX. The company searches for projects that could provide potential above-market returns.

To learn more about Lexaria Corp. visit www.lexariaenergy.com.

FOR FURTHER INFORMATION PLEASE CONTACT:
Lexaria Corp. Chris Bunka, CEO: (250) 765-6424
Clark Kent, Media Inquiries: (647) 519-2646

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. It is impossible to identify all such factors but they include and are not limited to the existence of underground deposits of commercial quantities of oil and gas; cessation or delays in exploration because of mechanical, weather, operating, financial or other problems; capital expenditures that are higher than anticipated; or exploration opportunities being fewer than currently anticipated. There can be no assurance that road or site conditions will be favorable for field work; no assurance that well treatments or workovers will have any effect on oil or gas production; no assurance that oil field interconnections will have any measurable impact on oil or gas production or on field operations, and no assurance that any expected new well(s) will be drilled or have any impact on the Company. There can be no assurance that expected oil and gas production will actually materialize; and thus no assurance that expected revenue will actually occur. There is no assurance the Company will have sufficient funds to drill additional wells, or to complete acquisitions or other business transactions. Such forward looking statements also include estimated cash flows, revenue and current and/or future rates of production of oil and natural gas, which can and will fluctuate for a variety of reasons; oil and gas reserve quantities produced by third parties; and intentions to participate in future exploration drilling. Adverse weather conditions including but not limited to surface flooding can delay operations, impact production, and cause reductions in revenue. The Company may not have sufficient expertise to thoroughly exploit its oil and gas properties. The Company may not have sufficient funding to thoroughly explore, drill or develop its properties. Access to capital, or lack thereof, is a major risk and there is no assurance that the Company will be able to raise required working capital. Current oil and gas production rates may not be sustainable and targeted production rates may not occur. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that the medical marijuana business will provide any benefit to Lexaria, and no assurance that any proposed new facility will be built or proceed, nor that municipal or Health Canada regulatory approvals will be obtained. There is no assurance that any municipality where proposed facilities are located will retain its approval for a medical marijuana production facility. The Company is not currently growing or selling medical marijuana.

The CNSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Start your small cap medical marijuana research in the AGORACOM Small Cap 
Medical Marijuana Stocks Gateway: 
http://agoracom.com/portal/Small%20Cap%20Medical%20Marijuana%20Stocks